Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients

Editorial: nocebo effect and switching to biosimilars

(2018) A. A. van Bodegraven et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The nocebo effect challenges the non-medical infliximab switch in practice

(2018) N. W. Boone et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France

(2018) Jérôme Avouac et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

The nocebo effect: a clinical challenge in the era of biosimilars

(2018) Lieven Pouillon et al.   Expert Review of Clinical Immunology

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab

(2018) Brian G. Feagan et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

(2018) Bente Glintborg et al.   ANNALS OF THE RHEUMATIC DISEASES

The PROSIT-BIO Cohort

(2017) Gionata Fiorino et al.   INFLAMMATORY BOWEL DISEASES

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

(2017) Kristin K Jørgensen et al.   LANCET

Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients

(2017) Anja Eberl et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Bad news: The influence of news coverage and Google searches on Gardasil adverse event reporting

(2017) Kate Faasse et al.   VACCINE

Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab

(2017) Lieke Tweehuysen et al.   Arthritis & Rheumatology

Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians

(2016) Hillel Cohen et al.   ADVANCES IN THERAPY

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study

(2016) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study

(2016) Dae Hyun Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

A systematic review of factors that contribute to nocebo effects.

(2016) Rebecca K. Webster et al.   HEALTH PSYCHOLOGY

Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn’s and Ulcerative Colitis Associations: Table 1.

(2016) Laurent Peyrin-Biroulet et al.   Journal of Crohns & Colitis

ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update

(2016) Silvio Danese et al.   Journal of Crohns & Colitis

Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study

(2016) Lisa J. T. Smits et al.   Journal of Crohns & Colitis

Biosimilars in IBD: from theory to practice

(2016) Silvio Danese et al.   Nature Reviews Gastroenterology & Hepatology

Patient attitudes and understanding about biosimilars: an international cross-sectional survey

(2016) Ira Jacobs et al.   Patient Preference and Adherence

Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data

(2015) Elena Nikiphorou et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study

(2015) Yoon Suk Jung et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

The AGA Institute Process for Developing Clinical Practice Guidelines Part One: Grading the Evidence

(2013) Shahnaz Sultan et al.   Clinical Gastroenterology and Hepatology

The nocebo effect: patient expectations and medication side effects

(2013) Kate Faasse et al.   POSTGRADUATE MEDICAL JOURNAL

Nocebo in clinical trials for depression: A meta-analysis

(2013) Dimos D. Mitsikostas et al.   PSYCHIATRY RESEARCH

To Tell the Truth, the Whole Truth, May Do Patients Harm: The Problem of the Nocebo Effect for Informed Consent

(2012) Rebecca Erwin Wells et al.   AMERICAN JOURNAL OF BIOETHICS

Nocebo Effects, Patient-Clinician Communication, and Therapeutic Outcomes

(2012) Luana Colloca et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches

(2011) Dimos D Mitsikostas et al.   CEPHALALGIA

A meta-analytic approach to estimating nocebo effects in neuropathic pain trials

(2011) Dimitrios Papadopoulos et al.   JOURNAL OF NEUROLOGY

Nocebo-Induced Hyperalgesia During Local Anesthetic Injection

(2010) Dirk Varelmann et al.   ANESTHESIA AND ANALGESIA

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

(2008) Gordon H Guyatt et al.   BMJ-British Medical Journal